Pharma companies outperform institutions in European clinical trial reporting amid problematic overall trends — Oxford study
Half of all trials supposed to be reported in a European database are not, despite clear legal requirements, researchers have found in the first such study of compliance, which also notes that pharma companies do better in this regard than academic institutions, charities and hospitals.
Combing through 7274 trials on the EU Clinical Trials Register (EUCTR) that have passed the due date for posting data, a team out of Oxford’s Evidence-Based Medicine DataLab noted that only 49.5% reported their results — meaning half of the time, trials sponsors have breached a 2012 European Commission guideline that mandates disclosure within 12 months of study completion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.